Allergan said that its profit for the current quarter, excluding non-recurring items, could come in at $393.9 million to $399.9 million, slightly lower than analysts’ estimate of $405.9 million. It said it saw net product sales (which are slightly less than total sales) of $1.585 billion to $1.66 billion in the quarter.

Allergan shares were down about 1% in midday trading to a market value of $27.5 billion.